GUARDANT HEALTH has partnered with SWOG on a study to use cell-free DNA testing to identify mechanisms of resistance and future treatment options in non-small cell lung cancer. SWOG chose Guardant360 as the blood test for a tumor genomic profiling study of approximately 600 lung cancer patients. The study will test patients at the time...
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
